VEGFA and serous adenocarcinoma: To investigate this possibility, we treated mice carrying xenografts of an ovarian clear cell carcinoma with sunitinib, a kinase inhibitor that targets VEGF action that is approved for use in patients with renal clear cell carcinoma, and demonstrated a response to sunitinib in the clear cell carcinoma xenograft but not in xenografts derived from three different high-grade serous carcinomas (Y. Z. Wang and C. B. Gilks, unpublished data).